Back to Knowledge Center
General Medicine

Hepatic Encephalopathy

A reversible decline in brain function caused by severe liver disease, leading to confusion, altered sleep, and hand tremors as toxins (like ammonia) build up in the blood.

Source: WHO / CDC / NIH Evidence Guidelines
Updated: Aug 13, 2026
3,824 Views
Red Flag Warning & Emergency Situations

Emergency Management: Status epilepticus or acute intracranial hypertension causing brainstem herniation (Cushing's triad: hypertension, bradycardia, irregular breathing).

Core Definition:

Hepatic Encephalopathy (HE) is a potentially reversible, progressive neuropsychiatric syndrome occurring in patients with acute liver failure, liver cirrhosis, or portosystemic shunts. It manifests as a spectrum of cognitive, psychiatric, and motor disturbances ranging from subtle changes in personality and sleep-wake cycles to deep coma. It is primarily caused by the accumulation of neurotoxins, specifically ammonia, in the systemic circulation due to impaired hepatic clearance.

Detailed Overview

HE is a defining complication of decompensated cirrhosis. The diseased liver fails to convert gut-derived ammonia into urea, and portal hypertension causes blood to shunt around the liver entirely. The resulting elevated ammonia crosses the blood-brain barrier, disrupting astrocyte function. HE is rarely an unprovoked event; it is almost always triggered by a precipitating factor such as infection, GI bleeding, dehydration, or constipation. Identifying and treating the precipitating cause is as important as lowering ammonia levels. Its clinical significance is profound, as the onset of HE marks a transition to advanced liver disease and is a key indication for liver transplant evaluation.

Epidemiology & Demographics

Occurs in 30-40% of patients with cirrhosis at some point during their clinical course. Minimal HE (covert) affects up to 80% of patients with cirrhosis. It is a major cause of hospital readmissions.

Etiological Mechanism

The foundational etiology is hepatocellular failure and/or the presence of portosystemic shunts (either spontaneous varices or iatrogenic like TIPS - Transjugular Intrahepatic Portosystemic Shunt). This creates the anatomical and physiological setup for HE. The acute episodes are driven by precipitants.

Primary Causes

Precipitants: Infections (Spontaneous Bacterial Peritonitis, UTI), Gastrointestinal bleeding (massive protein load in the gut), Constipation, Hypokalemia/Alkalosis (increases ammonia entry into brain), Dehydration/Diuretics, and CNS depressant drugs (benzodiazepines, opioids).

Ammonia is produced in the colon by bacterial metabolism of dietary protein and urea. Normally, the liver rapidly clears it via the urea cycle. In cirrhosis, portosystemic shunting and hepatocyte dysfunction allow ammonia to bypass liver metabolism and enter systemic circulation. Ammonia readily crosses the blood-brain barrier. Astrocytes take up ammonia and convert it to glutamine via glutamine synthetase. Massive glutamine accumulation acts as an intracellular osmolyte, causing astrocyte swelling and cerebral edema (severe in acute liver failure, low-grade in cirrhosis). This astrocytopathy disrupts neurotransmission, altering GABAergic tone (increasing neuroinhibition) and causing mitochondrial dysfunction and oxidative stress, manifesting clinically as encephalopathy.

Diagnostic Criteria & Guidelines

A clinical diagnosis based on the presence of altered mental status in a patient with known liver disease or portosystemic shunts, after excluding other metabolic, infectious, or intracranial causes of encephalopathy.

First-Line Treatment:

Lactulose (Non-absorbable disaccharide). Starting dose: 20-30 grams (30-45 mL) PO or via NG tube every 1-2 hours until a bowel movement occurs, then titrate to achieve 2-3 soft bowel movements daily. Lactulose lowers colonic pH, trapping ammonia as unabsorbable ammonium (NH4+), and acts as a cathartic to clear nitrogenous load. MUST actively search for and treat the precipitant (e.g., pan-culture and start antibiotics if SBP suspected).

Second-Line & Adjunctive Therapy

Rifaximin (Non-absorbable antibiotic) 550 mg PO BID. Added to Lactulose for patients who do not respond to Lactulose alone or for secondary prophylaxis after a recurrent episode. Rifaximin alters gut microbiota, reducing ammonia-producing bacteria.

Surgical & Procedural Management

Liver transplantation is the only definitive cure for the underlying hepatic dysfunction. Embolization of large spontaneous portosystemic shunts is sometimes performed in refractory cases.

Patient Counseling & Advice

Educate caregivers that confusion is a sign of medical urgency, not just 'acting out.' Ensure they understand Lactulose dosing is titrated to effect (2-3 soft stools/day), not a strict fixed dose.

Follow-Up & Monitoring Schedule

Monitor clinical mental status and frequency of bowel movements daily. Routine measuring of serum ammonia to monitor treatment response is NOT recommended.

Preventive Strategies

Secondary prophylaxis with Lactulose (and Rifaximin if recurrent). Maintaining daily bowel movements and prompt treatment of infections.

The development of overt HE carries a poor prognosis, with a 1-year survival rate of approximately 40% without liver transplantation.

Authoritative Sources & Evidence References
World Health Organization (WHO) & CDC Guidelines: Information compiled from current international clinical practice guidelines.

System Notice

Confirm Action